Atara defers $9M milestone payment to HCRx to Jan 2028; issues 400K share warrant

Atara Biotherapeutics, Inc.

HCRx agreed to extend $9.0M milestone payment due from June 30, 2026 to Jan 1, 2028.
Atara issued warrant to purchase 400K shares at $0.0001/share, exercisable immediately, no expiration.
CEO cites flexibility to address FDA Complete Response Letter (CRL) for tabelecleucel.
Tabelecleucel is approved in Europe for EBV+ PTLD; working with FDA for US path.
Warrant subject to 4.99% beneficial ownership limit; net number via cashless exercise.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Atara Biotherapeutics, Inc. amended Amendment with HCR Molag Fund, L.P. valued at $9.0 million (effective 2026-02-20).

Action: amendment
Agreement: credit facility
Counterparty: HCR Molag Fund, L.P.
Value: $9.0 million
Effective: 2026-02-20

Exact text from the filing

On February 20, 2026, Atara Biotherapeutics, Inc., (the “Company”) entered into an Amendment (the “Amendment”) to the Purchase and Sale Agreement dated as of December 20, 2022 (the “Agreement”) with HCR Molag Fund, L.P. (“HCR”). Under the terms of the Amendment, HCR agreed to amend the due date of the one-time of $9.0 million cash payment

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-062534

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.